{
  "id": "b960b3dc56b5993a",
  "title": "FDA Outlines Flexible Approach to CMC Oversight for Cell and Gene Therapies",
  "description": "20260112T204500Z",
  "content": "",
  "source": "onclive.com",
  "source_url": "https://www.onclive.com/view/fda-outlines-flexible-approach-to-cmc-oversight-for-cell-and-gene-therapies",
  "published_at": "20260112T204500Z",
  "fetched_at": "2026-01-13T00:20:01.657666+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.onclive.com/view/fda-outlines-flexible-approach-to-cmc-oversight-for-cell-and-gene-therapies",
    "url_mobile": "",
    "title": "FDA Outlines Flexible Approach to CMC Oversight for Cell and Gene Therapies",
    "seendate": "20260112T204500Z",
    "socialimage": "https://cdn.sanity.io/images/0vv8moc6/onclive/8c0f0d93d445fed80918314ef7bfd03c9aee416c-1280x720.png",
    "domain": "onclive.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}